@curator

3 years ago

Article

Cabozantinib Plus Nivolumab/Ipilimumab Under Exploration in Intermediate-, Poor-Risk RCC

Rating: 0.0

Likes: 1

Library: 1

Cabozantinib Plus Nivolumab/Ipilimumab Under Exploration in Intermediate-, Poor-Risk RCC

November 14, 2020 - A novel combination comprised of the TKI cabozantinib plus the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab is under exploration in treatment-naïve patients with intermediate or poor risk advanced or metastatic renal cell carcinoma in the phase 3 COSMIC-313 trial.

Rate This Post

Rate The Educational Value

Rate The Ease of Understanding and Presentation

Interesting or Boring? Rate the Entertainment Value

Related Topics

exploration intermediate cabozantinib nivolumab ipilimumab poor risk trains health

Learning is Fun!

Close

Learning is Fun!

Close

Learning is Fun!

Close

Learning is Fun!

Close

Learning is Fun!

Close

Learning is Fun!

Close

Add articles, eBooks or videos to your Library.
You can revisit, watch or read your favorite items later

Learning is Fun!

Close

Unlocking the Power of Knowledge
for Humanity's Progress

By harnessing the power of Artificial Intelligence, Boostlane is changing the way we engage with information, connect with experts, and foster personal growth.

Explore Topics,
Discover Ideas,
Share knowledge,
Learn from Experts

Boostlane is a media platform that aims to revolutionize how we research, discover, and learn about our favorite topics

Boostlane relies on the power of Artificial Intelligence and a Community of Researchers to curate and deliver reliable, insightful, and purposeful knowledge

Support a platform focused on research and useful knowledge.
Create personalized feeds.
Follow your favorite topics and learn something new every day.
Learn with the assistance of people and Artificial Intelligence Systems.
Use innovative features designed to organize information and foster personal growth.
Collect your favorite media in your private Library.

Learning is Fun!

Close

Learning is Fun!

Close

Learning is Fun!

Close

Unlocking the Power of Knowledge
for Humanity's Progress

By harnessing the power of Artificial Intelligence, Boostlane is changing the way we engage with information, connect with experts, and foster personal growth.

Explore Topics,
Discover Ideas,
Share knowledge,
Learn from Experts

Boostlane is a media platform that aims to revolutionize how we research, discover, and learn about our favorite topics

Boostlane relies on the power of Artificial Intelligence and a Community of Researchers to curate and deliver reliable, insightful, and purposeful knowledge

Support a platform focused on research and useful knowledge.
Create personalized feeds.
Follow your favorite topics and learn something new every day.
Learn with the assistance of people and Artificial Intelligence Systems.
Use innovative features designed to organize information and foster personal growth.
Collect your favorite media in your private Library.

Cabozantinib Plus Nivolumab/Ipilimumab Under Exploration in Intermediate-, Poor-Risk RCC

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge
for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge
for Humanity's Progress

Cabozantinib Plus Nivolumab/Ipilimumab Under Exploration in Intermediate-, Poor-Risk RCC

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress